Zoetis NYSE: ZTS reported second-quarter revenue of $2.5 billion, flat on a reported basis and down 1% organically, as pressure in U.S. companion-animal categories offset growth in livestock, diagnostics and international markets. Adjusted net income was $781 million, down 2% organically, while adjusted diluted earnings per share rose 4% to $1.87, benefiting from a lower share count following share repurchases.
Zoetis cuts its 2026 outlook as weaker vet traffic, price sensitivity and competition pressure in Companion Animal, while promotions aim to defend share.
Zoetis Inc. (ZTS) Q2 2026 Earnings Call Transcript
| Specialty Retail Industry | Consumer Discretionary Sector | Kristin C. Peck CEO | SIX Exchange | US98978V1035 ISIN |
| US Country | 14,500 Employees | 20 Jul 2026 Last Dividend | - Last Split | 1 Feb 2013 IPO Date |
Zoetis Inc. is a global leader in the discovery, development, manufacture, and commercialization of a wide range of animal health medicines, vaccines, and diagnostic products. Founded in 1952 and based in Parsippany, New Jersey, the company addresses the health needs of both livestock—including cattle, swine, poultry, fish, and sheep—and companion animals, such as dogs, cats, and horses. With a presence in both the United States and international markets, Zoetis delivers products and services designed to meet the complex challenges of animal health, ensuring the well-being of animals across the globe. The company's extensive product line-up, alongside innovative diagnostic solutions, makes it a vital player in promoting animal health and supporting the veterinarians, livestock producers, and pet owners who care for them.
Zoetis Inc. offers an expansive portfolio of products and services designed to enhance animal health and support the professionals who work with animals. These include: